Siemens Healthineers AG (OTCMKTS:SMMNY) Given Consensus Rating of “Buy” by Analysts

Shares of Siemens Healthineers AG (OTCMKTS:SMMNY) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company.

A number of analysts have recently weighed in on SMMNY shares. Zacks Research raised shares of Siemens Healthineers from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Citigroup reaffirmed a “buy” rating on shares of Siemens Healthineers in a research report on Friday, January 23rd. Finally, Sanford C. Bernstein raised shares of Siemens Healthineers to a “strong-buy” rating in a research report on Tuesday, January 13th.

Siemens Healthineers Stock Down 2.6%

OTCMKTS:SMMNY opened at $21.54 on Monday. The firm’s 50-day moving average price is $22.59 and its 200-day moving average price is $24.89. Siemens Healthineers has a 1-year low of $20.39 and a 1-year high of $28.92.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.